We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Sareum Holdings plc (SAR) ORD GBP0.0125

Sell:190.00p Buy:195.00p 0 Change: 12.50p (6.94%)
Market closed Prices as at close on 24 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:190.00p
Buy:195.00p
Change: 12.50p (6.94%)
Market closed Prices as at close on 24 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:190.00p
Buy:195.00p
Change: 12.50p (6.94%)
Market closed Prices as at close on 24 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sareum Holdings plc is a United-Kingdom based holding company. It is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry, and medicinal chemistry. Its drug programs include Checkpoint Kinase 1 (Chk1), TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. The Checkpoint Kinase 1 (Chk1) inhibitor SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA damage response (DDR) network. The TYK2/JAK1 are both members of the Janus kinase (JAK) family of protein kinase enzymes with important roles in maintaining a healthy immune system. Both kinases promote inflammatory responses in autoimmune diseases, respiratory infections and tumor cell proliferation in certain cancers. Aurora+FLT3 Kinase Programme targets Acute Myeloid Leukemia (AML) and other blood cancers.

Contact details

Address:
Unit 2A
Langford Arch, London Road, Pampisford
CAMBRIDGE
CB22 3FX
United Kingdom
Telephone:
+44 (01223) 497700
Website:
www.sareum.co.uk/

Important dates

Future events
There are no future events available.
Past events
General meeting 28 February 2022 28/02/22
Interim results 21 February 2022 21/02/22
AGM 16 December 2021 16/12/21
Final results 25 October 2021 25/10/21
Trading Announcement 18 August 2021 18/08/21

General stock information

EPIC:
SAR
ISIN:
GB00BMC3RJ87
Market cap:
£131.03 million
Shares in issue:
68.07 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Tim Mitchell
    Chief Executive Officer, Founder, Executive Director
  • John Reader
    Founder, Chief Scientific Officer, Executive Director
  • Tony Bunn
    Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.